Monoamine Oxidase Inhibitors

@article{Livingston1996MonoamineOI,
  title={Monoamine Oxidase Inhibitors},
  author={Martin G. Livingston and Hilary M. Livingston},
  journal={Drug Safety},
  year={1996},
  volume={14},
  pages={219-227}
}
SummaryAfter initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Despite their clinical benefits, this has led to a reduction in use of such medications.Discovery of the 2 main subgroups of monoamine oxidase, types A and B, led to the synthesis of MAOIs selective for one or… Expand
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical,Expand
Monoamine oxidase inhibitors (including the newer reversible compounds)
In the mid-1950s the chance finding of iproniazid’s mood-elevating properties [1] led to the discovery that inhibition of monoamine oxidase (MAO) results in changes in cerebral function. MonoamineExpand
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of majorExpand
Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo.
TLDR
Strong evidence is provided that lamotrigine did not modulate oral tyramine-induced hypertension in rats or 5-hydroxytryptophan-induced head shaking in mice, providing strong evidence that the drug does not perturb monoamine metabolism in vivo. Expand
Pharmacotherapy of depression: a historical analysis
  • T. Ban
  • Psychology, Medicine
  • Journal of Neural Transmission
  • 2001
TLDR
Although one can no longer expect that 2 of 3 depressed patients will respond to treatment, the newer antidepressants are better tolerated, because they produce less anticholinergic side effects. Expand
Transdermal selegiline for the treatment of major depressive disorder
TLDR
The introduction of EMSAM overcomes many of the safety concerns affiliated with the conventional oral MAO inhibitors and EMSAM may be considered another strategy for the treatment of MDD, especially in patients who cannot tolerate oral antidepressants, are poorly adherent, who present with atypical depressive symptoms, or have failed other antidepressants. Expand
Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease
TLDR
A 45-year-old Japanese man with Parkinson’s disease who developed paroxysmal hypertensive crises when selegiline was added to his daily treatment regimen of levodopa and dopamine agonists is reported. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Selegiline Transdermal System: In the Treatment of Major Depressive Disorder
TLDR
Data from three randomized controlled trials showed a significantly better efficacy of STS in the treatment of unipolar major depression in comparison with placebo during 6–8 weeks of treatment, and one long-term randomized controlled trial demonstrated the efficacy of theSTS in relapse prevention of un bipolar depression over 1 year. Expand
Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.
TLDR
The present work reviews, from a historical perspective, the entire process that led to the discovery of these drugs, as well as their contribution to the development of the neuroscientific disciplines. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors
TLDR
Overall, RIMAs appear to represent therapeutic progress in the treatment of depression in terms of both efficacy and tolerability. Expand
Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.
  • A. J. Cooper
  • Medicine
  • The British journal of psychiatry. Supplement
  • 1989
TLDR
Second-generation MAOIs which are selective for monoamine oxidase-A and B are now being synthesised and may eliminate the eventuality of hypertension without special dietary precautions. Expand
Towards rational therapy with monoamine oxidase inhibitors.
  • P. Tyrer
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1976
TLDR
A rational approach to the use of monoamine oxidase inhibitors (MAOIs) is outlined, and great variation in the interval between the first administration of these drugs and clinical response may account for the inconsistencies in published trials. Expand
A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.
TLDR
It was concluded that (-)-deprenyl is an effective antidepressant in a dose range where it is distinguished by the absence of many of the side effects typical of nonselective MAO inhibitors. Expand
Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
The present status of monoamine oxidase inhibitors.
  • C. Pare
  • Psychology, Medicine
  • The British journal of psychiatry : the journal of mental science
  • 1985
TLDR
With adequate doses they are effective antidepressants, but dosages have in the past been too low and should not deter doctors from using these drugs, especially in those depressed patients who do not respond to tricyclic-type antidepressants. Expand
Combining tricyclic and monoamine oxidase inhibitor antidepressants.
TLDR
It is concluded that the use of a MAOI-tricyclic combination in oral therapeutic doses is safe, but the efficacy of this combination has not yet been proved, and it may be particularly toxic if taken in an overdose. Expand
A review of combined tricyclic and MAOI therapy.
TLDR
It appears that combined antidepressant therapy, if properly administered, leads to neither serious complications nor to inordinate number of minor side effects. Expand
Combined MAOI-tricyclic antidepressant treatment: a reevaluation.
TLDR
The hazards of combination therapy have been exaggerated and that MAOI-tricyclic therapy is a reasonable approach in patients found resistant to standard antidepressant treatment if certain precautions are observed. Expand
Serotonin syndrome caused by a moclobemide-clomipramine interaction.
TLDR
A 7T year old woman with depression and Parkinson's disease has a case of serotonin syndrome induced by the reversible monoamine oxidase A inhibitor moclobemide and the serotonin reuptake inhibitor clomipramine, and fulfilled the diagnostic criteria for the serotonin syndrome suggested by Sternbach. Expand
...
1
2
3
4
...